Real World Comparison of Asciminib Versus Ponatinib in Chronic Myeloid Leukemia with Propensity Score-Matched Analysis
Chronic myeloid leukemia (CML) has an excellent prognosis with tyrosine kinase inhibitors (TKIs); however, approximately 40-50% of patients discontinue at least one TKI because of resistance or intolerance. While Ponatinib (PON) is highly effective against resistant disease, Asciminib (ASC) offers robust efficacy with favorable tolerability profile. In the absence of randomized head-to-head trials, we compared outcomes of ASC versus PON using propensity score-matched (PSM) analysis. We conducted a real-world analysis of 762 CML patients previously treated with ≥1 TKI (ASC, n=451; PON, n=311), from an international multicenter cohort. PSM generated 139 balanced pairs after adjusting for age, prior TKI exposure, cardiovascular history, ABL kinase domain mutations, and reason for prior TKI failure. The primary endpoints, evaluated in the matched cohort, were 12-month failure-free survival (FFS) and event-free survival (EFS). ASC was associated with similar molecular response rates and FFS to PON, while EFS was significantly longer with ASC, likely reflecting its more favorable tolerability and lower rate of discontinuation due to intolerance. The difference in EFS was particularly pronounced among patients treated for prior TKI intolerance and in lower-risk subgroups. A sensitivity analysis restricted to patients naïve to both agents (117 matched pairs) confirmed the EFS difference (12-month EFS, 88.6% vs 73.2%; HR 2.48; p=0.002). ASC was associated with similar molecular response and FFS outcomes to PON These findings suggest that ASC was associated with similar real-world molecular response and FFS outcomes to PON, while EFS was longer with ASC, largely driven by differences in treatment discontinuation related to intolerance. ASC may represent an attractive option for patients with prior TKI intolerance, while PON remains an important treatment option for patients with resistant disease.
Authors
- Swe Mar Linn (ORCID: https://orcid.org/0000-0002-3587-7158)
- Hana Klamová (ORCID: https://orcid.org/0009-0000-5020-7040)
- Simone Claudiani (ORCID: https://orcid.org/0000-0003-3686-7610)
- Peter E. Westerweel (ORCID: https://orcid.org/0000-0002-0746-7039)
- Gopila Gupta (ORCID: https://orcid.org/0000-0002-8909-1249)
- Christophe Bouvier
- Shinya H Kimura (ORCID: https://orcid.org/0000-0003-1717-6208)
- Petra Čičátková (ORCID: https://orcid.org/0000-0002-7412-7544)
- Andrew J. Innes (ORCID: https://orcid.org/0000-0003-0918-8882)
- Fausto Castagnetti (ORCID: https://orcid.org/0000-0002-0602-2628)
- Valentín García‐Gutiérrez (ORCID: https://orcid.org/0000-0003-4752-0815)
- Hassan Abdulmaoula Sibai (ORCID: https://orcid.org/0000-0001-9030-8583)
- Julien Bollard (ORCID: https://orcid.org/0000-0002-9378-5665)
- Emilia Scalzulli
- Delphine Réa (ORCID: https://orcid.org/0000-0001-5379-7461)
- Camille C.B. Kockerols (ORCID: https://orcid.org/0000-0002-6198-7035)
- María Agustina Perusini (ORCID: https://orcid.org/0000-0003-1893-6096)
- Mary Lynn Savoie (ORCID: https://orcid.org/0000-0003-0301-5139)
- Daniela Žáčková (ORCID: https://orcid.org/0000-0001-9802-8148)
- Jane F. Apperley (ORCID: https://orcid.org/0000-0002-1710-1794)
- Hiroshi Ureshino (ORCID: https://orcid.org/0000-0002-5034-3699)
- Tomoiku Takaku (ORCID: https://orcid.org/0000-0002-6493-6225)
- Sung‐Eun Lee (ORCID: https://orcid.org/0000-0002-9810-2050)
- Dennis Dong Hwan Kim (ORCID: https://orcid.org/0000-0003-2640-4911)
- Dragana Milojković (ORCID: https://orcid.org/0000-0002-0593-8220)
- Massimo Breccia (ORCID: https://orcid.org/0000-0003-1163-6162)
- Carmen Fava (ORCID: https://orcid.org/0000-0002-4896-981X)
- Carolina Pavlovsky
- Franck E. Nicolini
- Jiří Mayer
Institutions
- Hiroshima University (JP)
- Imperial College Healthcare NHS Trust (GB)
- Inserm (FR)
- University of Calgary (CA)
- Saga University (JP)
- University of Toronto (CA)
- Hammersmith Hospital (GB)
- Erasmus MC (NL)
- Princess Margaret Cancer Centre (CA)
- Albert Schweitzer Ziekenhuis (NL)
- Institute of Haematology and Blood Transfusion (CZ)
- Assistance Publique – Hôpitaux de Paris (FR)
- University Hospital Brno (CZ)
- Centre Léon Bérard (FR)
- Alberta Cancer Foundation (CA)
- Centre de Recherche en Cancérologie de Lyon (FR)
- Fundación para la Investigación, Docencia y Prevención del Cáncer (AR)
- Hôpital Saint-Louis (FR)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Hospital Universitario Ramón y Cajal (ES)
- Arthur J.E. Child Comprehensive Cancer Centre (CA)
- Imperial College London (GB)
- University of Turin (IT)
- Saitama Medical University (JP)
- Sapienza University of Rome (IT)
- Catholic University of Korea (KR)
- University of Bologna (IT)
Publication Details
- Journal
- Blood Advances
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1182/bloodadvances.2026021475
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00